HSP90AA1 and plasma cell myeloma: The treatment of cytotoxic T lymphocytes engineered to target HSP27- and HSP90-specific peptides effectively decreased the tumor growth in a myeloma xenograft mouse model, suggesting the HSPs as tumor associated antigens (TAA) for myeloma immunotherapy [138].